Specific Inhibition of CBP/beta-catenin Interaction Rescues Defects in Neuronal Differentiation Caused by a Presenilin-1 Mutation
Overview
Affiliations
Wnt/beta-catenin signaling has been shown to promote self-renewal in a variety of tissue stem cells, including neuronal stem cells and hematopoietic stem cells. However, activation of the Wnt/beta-catenin pathway promoted and inhibition of the pathway prevented differentiation of neuronal precursor cells. A clear explanation for the differential effects of Wnt/beta-catenin activation on neuronal precursors is not available at present. Presenilin-1 (PS-1) is a polytopic protein comprised of six to eight transmembrane domains. PS-1, as part of the gamma-secretase complex, is required for the intramembrane proteolysis of both amyloid precursor protein (APP) and Notch. Additionally, through interactions with beta-catenin, PS-1 is associated with modulation of Wnt/beta-catenin signaling. A familial Alzheimer's disease-associated PS-1 mutant, PS-1(L286V), causes a dramatic increase in T cell factor (TCF)/beta-catenin transcription in PC-12 cells, which prevents normal nerve growth factor (NGF)-induced neuronal differentiation and neurite outgrowth. Selective inhibition of TCF/beta-catenin/cAMP-response element-binding protein (CREB)-binding protein (CBP)-mediated transcription, but not TCF/beta-catenin/p300, with the recently described small molecule antagonist ICG-001 corrects these defects in neuronal differentiation, highlighting the importance of Wnt/beta-catenin signaling in this process. We propose that increased TCF/beta-catenin/CBP-mediated transcription, as well as a failure to switch to TCF/beta-catenin/p300-mediated transcription, play an important role in decreasing neuronal differentiation.
Targeting CBP and p300: Emerging Anticancer Agents.
Masci D, Puxeddu M, Silvestri R, La Regina G Molecules. 2024; 29(19).
PMID: 39407454 PMC: 11482477. DOI: 10.3390/molecules29194524.
Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?.
de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, Prevostel C Pharmaceuticals (Basel). 2024; 17(7).
PMID: 39065798 PMC: 11279613. DOI: 10.3390/ph17070949.
Zhou Y, He Z, Li T, Choppavarapu L, Hu X, Cao R Cancers (Basel). 2024; 16(12).
PMID: 38927910 PMC: 11201718. DOI: 10.3390/cancers16122202.
Park C, Yoshihara H, Gao Q, Qu C, Iacobucci I, Ghate P Cell Rep. 2023; 42(7):112804.
PMID: 37453060 PMC: 10529385. DOI: 10.1016/j.celrep.2023.112804.
Ouchi H, Mizutani Y, Yoshimura K, Sato Y, Kimura K, Haruyama Y Med Mol Morphol. 2023; 56(2):94-105.
PMID: 36645521 DOI: 10.1007/s00795-022-00343-8.